Long-Term Glycemic Control in Type 2 Diabetes \u2013 Key Points
\nSource : Medscape 9 March, 2026<\/p>\n
\u2022\u2060 \u2060The most accurate statement: Glycemic control reduces the risk of diabetes-related microvascular complications (chosen by 81% of respondents).<\/p>\n
\u2022\u2060 \u2060Elevated blood glucose is strongly associated with microvascular complications such as retinopathy, nephropathy, and neuropathy.<\/p>\n
\u2022\u2060 \u2060According to the American Diabetes Association (ADA), improving long-term glycemic control lowers the risk of these complications.<\/p>\n
\u2022\u2060 \u2060Glycemic management does not replace cardiovascular risk management; diabetes care must also address lipids, blood pressure, and lifestyle factors.<\/p>\n
\u2022\u2060 \u2060ADA guidance suggests optimizing glycemic management when triglycerides \u2265150 mg\/dL or HDL is low (<50 mg\/dL in women, <40 mg\/dL in men).
\n\u2022\u2060 \u2060\u2060LDL-C target (ADA Standards of Care):
\n\u2013 <70 mg\/dL for adults with diabetes at high cardiovascular risk(2 1RF, or DM <10yrs)
\n\u2013 <55 mg\/dL for patients with established ASCVD or very high risk(BM with multiple RF, DM<10yrs or with vascular disease) or <40 in poly vascular disease.<\/p>\n